Pharmaceuticals, Biotechnology and Life Sciences
Bavarian Nordic has announced an additional worldwide exclusive license and collaboration agreement with Janssen Pharmaceuticals, which grants Janssen the exclusive rights to Bavarian Nordic’s MVA-BN technology for two programs, targeting vaccines against hepatitis B virus (HBV) and the human immunodeficiency virus (HIV-1).
Janssen Research & Development, said Wednesday the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for Xarelto (rivaroxaban).
The U.S. FDA will review a supplemental New Drug Application for Janssen’s Imbruvica for chronic graft-versus-host-disease after failed certain therapies.
Bayer AG and Janssen Pharmaceuticals reported results from a study called Einstein Choice on Saturday.
Jansen revealed results from its real-world study of its cancer drug Zytiga in combination with Prednisone, to treat men with prostate cancer.
Biocartis has today strenghten its collaboration with two companies; J&J’s Jansen and Amgen, as it has submitted 510(k) its diagnostics…
Janssen Biotech has submitted two Supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) seeking approval…
Janssen Biotech is looking to expand the usage of its prescription drug Stelara, as it has asked the U.S. Food…
Janssen Pharmaceuticals, Inc. (Janssen) has entered into a definitive collaboration and license agreement with Bavarian Nordic to leverage their MVA-BN technology, jointly with Janssen’s own AdVac technology, in the development and commercialization of a heterologous prime-boost vaccine for the treatment of Human Papillomavirus (HPV) chronic infections which can lead to cancer.
Janssen Biotech, Inc. and Janssen-Cilag International NV (Janssen) are seeking approval from the U.S. and European authorities for Chron’s disease drug Stelara.